Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-331-3p inhibitor
- Development stage
- Preclinical
- Lead developer
- University Hospital Halle (Saale)
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
miR-331-3p inhibitor is an experimental RNA-based therapeutic designed to block the activity of microRNA-331-3p. In the context of cardiovascular disease, miR-331-3p has been identified as a promoter of vascular remodeling in atherosclerosis by modulating the proliferation, migration, and phenotypic switching of smooth muscle cells (SMCs). Inhibition of this microRNA has been shown to reduce SMC migration and promote anti-apoptotic effects in SMCs while sparing endothelial cell function. Key downstream targets regulated by miR-331-3p inhibition include Dual specificity protein phosphatase 5 (DUSP5) and PH domain and leucine-rich repeat protein phosphatase 1 (PHLPP1), as well as KLF16, BAK1, SOCS1, TNFα, and TGFBR1. This approach represents a potential strategy for treating atherosclerosis and related cardiovascular conditions.
- Other names
- miR-331-3p antagomirmiR331-3p antagomirmiR 331-3p antagomirmicroRNA-331-3p inhibitormicroRNA331-3p inhibitormicroRNA 331-3p inhibitor
02
Targets
miR-331-3p (MicroRNA-331-3p)pre-miR-331 (Pre-microRNA-331)
Beyond the preview
Go deeper on miR-331-3p inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-331-3p inhibitor.